Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses

J Pharm Pharmacol. 2002 Sep;54(9):1195-203. doi: 10.1211/002235702320402035.

Abstract

Intranasal immunization offers potential forthe elicitation of effective mucosal and systemic immune responses. In this study, a previously reported novel cationic nanoparticle engineered from a microemulsion precursor was further modified, optimized and applied intranasally to mice to explore its potential as a plasmid DNA (pDNA) vaccine delivery system. To this end, more uniform nanoparticles (around 100 nm) containing less cationic surfactant were developed. The pDNA-coated nanoparticles significantly enhanced the specific serum IgG and IgA titres to an expressed model antigen, beta-galactosidase, by 18-28 and 25-30 fold, respectively, when compared with naked pDNA alone. An enhanced splenocyte proliferative response was also observed after immunization with the pDNA-coated nanoparticles. It was concluded that these plasmid DNA-coated nanoparticles may have potential for immunization via the nasal route.

MeSH terms

  • Administration, Intranasal
  • Animals
  • Drug Delivery Systems
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Particle Size
  • Plasmids / administration & dosage*
  • Plasmids / immunology
  • Polyethylene Glycols
  • Vaccines / administration & dosage
  • Vaccines / immunology*

Substances

  • Vaccines
  • Polyethylene Glycols
  • octadecyl polyoxyethylene ether